Drug intelligence / Profile preview

NKIRA

Development stage: Preclinical
Lead developer: KWHC
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

NKIRA is a preclinical-stage natural killer (NK) cell immunotherapy developed by KWHC (KWEHEALTH). The therapy is designed to harness the innate ability of NK cells to identify and mediate cytotoxicity against diseased or malignant cells. NKIRA is part of a broader pipeline of cell and exosome-based therapies derived from perinatal tissues. While specific molecular targets and clinical indications have not been disclosed, the program is positioned within the field of regenerative medicine and oncology, focusing on the use of specialized cells to treat complex diseases.

Targets

ERN1 (Inositol-requiring enzyme 1 alpha)

Beyond the preview

Go deeper on NKIRA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKIRA.

Explore the full profile